Carisma advances macrophage immunotherapy

By The Science Advisory Board staff writers

July 27, 2020 -- Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug (IND) application through the U.S. Food and Drug Administration. The company intends to initiate a phase I clinical trial for the candidate this year.

The company's lead candidate, CT-0508, is a chimeric antigen receptor macrophage (CAR-M) that is targeted at anti-human epidermal growth factor receptor 2 (HER2). The phase I clinical trial will be evaluated in patients with recurrent or metastatic HER2 overexpressing solid tumors after failure of approved HER2-targeted agents. The clinical trials will be conducted at two trial sites at the University of Pennsylvania and the University of North Carolina at Chapel Hill.

Preclinical findings suggest that the company's CAR-M therapy could provide broad immune responses against solid tumors. The acceptance of the IND marks Carisma's transition from a discovery-based firm to a clinical development stage company.

The company also announced that it has expanded its board of directors and scientific advisory board.

Kite to manufacture CAR T-cell therapy in Europe
Gilead subsidiary Kite has received approval from the European Medicine Agency for end-to-end manufacturing of individualized cell therapies at its European...
CARsgen receives IND clearance for cell therapy
CARsgen Therapeutics has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration for a cell therapy drug for advanced...
Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...

Copyright © 2020

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter